Samsung Bioepis and Harrow Strengthen SB11 Clinical Evidence
INCHEON, South Korea & NASHVILLE, Tenn., July 20, 2026 Samsung Bioepis Co., Ltd. and Harrow, Inc. have presented positive...
ASRS 2026
Advertisement
Belite Bio Reports Positive Phase 3 Tinlarebant Data at ASRS 2026
SAN DIEGO, July 20, 2026 Belite Bio, Inc. (NASDAQ: BLTE) announced additional positive secondary endpoint data from its Phase...
SystImmune Advances Oncology Portfolio with Iza-bren Approval
REDMOND, Wash., July 17, 2026 SystImmune Inc. announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd., has received...
Harrow Highlights New IHEEZO and BYOOVIZ Clinical Evidence at ASRS 2026
NASHVILLE, Tenn., July 20, 2026 Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,...
REGENXBIO Reports Positive Long-Term Gene Therapy Results
ROCKVILLE, Md., July 18, 2026 REGENXBIO Inc. has announced positive long-term clinical data for its investigational one-time gene therapy,...
Advertisements
4DMT Reports Positive 2-Year PRISM Phase 2b Data for 4D-150
EMERYVILLE, Calif., July 18, 2026 4D Molecular Therapeutics (4DMT) announced positive two-year results from its PRISM Phase 2b clinical...
Annexon Advances Vonaprument with Phase 2 Data
BRISBANE, Calif., July 14, 2026 Annexon announced that new analyses from its Phase 2 ARCHER trial evaluating vonaprument in...
Belite Bio Highlights DRAGON Trial at ISCEV and ASRS
SAN DIEGO, July 6, 2026 Belite Bio announced that new clinical data from its Phase 3 DRAGON trial evaluating...
REGENXBIO Doses First Patient in NAAVIGATE Gene Trial
ROCKVILLE, Md., June 29, 2026 REGENXBIO Inc. has reached a major milestone in the advancement of gene therapy for...
Advertisement
